FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890774149> ?p ?o ?g. }

• W2890774149 endingPage "e000692" @default.
• W2890774149 startingPage "e000692" @default.
• W2890774149 abstract "Objective To conduct subset analyses of SPIRIT-P2 ( NCT02349295 ) to investigate the efficacy and safety of ixekizumab versus placebo in three subgroups of patients with active psoriatic arthritis (PsA) according to the concomitant conventional synthetic disease-modifying antirheumatic drug (cDMARD) received: any background cDMARDs (including methotrexate), background methotrexate only, or none. Methods Patients were randomised to receive placebo, ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W). Efficacy and safety were assessed when patients were subdivided according to cDMARD use at baseline. Efficacy was evaluated versus placebo at week 24 by the American College of Rheumatology criteria (ACR20/50), achievement of minimal disease activity (MDA) state, Disease Activity Index for PsA (DAPSA), 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP), Health Assessment Questionnaire-Disability Index and the 36-item Short-Form health survey physical functioning domain. Results Regardless of background cDMARD status, ACR20, ACR50 and MDA response rates were significantly higher than placebo with IXEQ4W or IXEQ2W treatment. Similarly, significant improvements were observed relative to placebo for DAS28-CRP and DAPSA across subgroups. Physical function also significantly improved relative to placebo with IXEQ4W treatment regardless of background cDMARD status and with IXEQ2W alone. Percentages of reported treatment-emergent adverse events (AEs), serious AEs (including serious infections) and discontinuations due to AEs in each subgroup were comparable to the overall SPIRIT-P2 population. Conclusion Ixekizumab was efficacious in patients with active PsA and previous tumour necrosis factor inhibitor (TNFi) inadequate response or TNFi intolerance treated with ixekizumab alone or when added to cDMARDs with subgroup safety profiles that were consistent with that observed in the overall SPIRIT-P2 population." @default.
• W2890774149 created "2018-09-27" @default.
• W2890774149 creator A5000010047 @default.
• W2890774149 creator A5007118333 @default.
• W2890774149 creator A5011826741 @default.
• W2890774149 creator A5012842018 @default.
• W2890774149 creator A5015084747 @default.
• W2890774149 creator A5083457214 @default.
• W2890774149 creator A5090992937 @default.
• W2890774149 date "2018-09-01" @default.
• W2890774149 modified "2023-10-17" @default.
• W2890774149 title "Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors" @default.
• W2890774149 cites W2018829324 @default.
• W2890774149 cites W2058212772 @default.
• W2890774149 cites W2068614670 @default.
• W2890774149 cites W2103524303 @default.
• W2890774149 cites W2113717019 @default.
• W2890774149 cites W2116843833 @default.
• W2890774149 cites W2128325185 @default.
• W2890774149 cites W2133696182 @default.
• W2890774149 cites W2145778588 @default.
• W2890774149 cites W2149168537 @default.
• W2890774149 cites W2159106700 @default.
• W2890774149 cites W2167795826 @default.
• W2890774149 cites W2167894048 @default.
• W2890774149 cites W2171889601 @default.
• W2890774149 cites W2197185666 @default.
• W2890774149 cites W2258730682 @default.
• W2890774149 cites W2339525054 @default.
• W2890774149 cites W2402355081 @default.
• W2890774149 cites W2418506270 @default.
• W2890774149 cites W2494623485 @default.
• W2890774149 cites W2512436288 @default.
• W2890774149 cites W2620369605 @default.
• W2890774149 cites W2781361933 @default.
• W2890774149 cites W4245195207 @default.
• W2890774149 doi "https://doi.org/10.1136/rmdopen-2018-000692" @default.
• W2890774149 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6135452" @default.
• W2890774149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30233812" @default.
• W2890774149 hasPublicationYear "2018" @default.
• W2890774149 type Work @default.
• W2890774149 sameAs 2890774149 @default.
• W2890774149 citedByCount "16" @default.
• W2890774149 countsByYear W28907741492019 @default.
• W2890774149 countsByYear W28907741492020 @default.
• W2890774149 countsByYear W28907741492021 @default.
• W2890774149 countsByYear W28907741492022 @default.
• W2890774149 countsByYear W28907741492023 @default.
• W2890774149 crossrefType "journal-article" @default.
• W2890774149 hasAuthorship W2890774149A5000010047 @default.
• W2890774149 hasAuthorship W2890774149A5007118333 @default.
• W2890774149 hasAuthorship W2890774149A5011826741 @default.
• W2890774149 hasAuthorship W2890774149A5012842018 @default.
• W2890774149 hasAuthorship W2890774149A5015084747 @default.
• W2890774149 hasAuthorship W2890774149A5083457214 @default.
• W2890774149 hasAuthorship W2890774149A5090992937 @default.
• W2890774149 hasBestOaLocation W28907741491 @default.
• W2890774149 hasConcept C126322002 @default.
• W2890774149 hasConcept C142724271 @default.
• W2890774149 hasConcept C197934379 @default.
• W2890774149 hasConcept C198451711 @default.
• W2890774149 hasConcept C204787440 @default.
• W2890774149 hasConcept C27081682 @default.
• W2890774149 hasConcept C2776260265 @default.
• W2890774149 hasConcept C2777575956 @default.
• W2890774149 hasConcept C2779384505 @default.
• W2890774149 hasConcept C2779745271 @default.
• W2890774149 hasConcept C2779786854 @default.
• W2890774149 hasConcept C2781059491 @default.
• W2890774149 hasConcept C2908647359 @default.
• W2890774149 hasConcept C71924100 @default.
• W2890774149 hasConcept C99454951 @default.
• W2890774149 hasConceptScore W2890774149C126322002 @default.
• W2890774149 hasConceptScore W2890774149C142724271 @default.
• W2890774149 hasConceptScore W2890774149C197934379 @default.
• W2890774149 hasConceptScore W2890774149C198451711 @default.
• W2890774149 hasConceptScore W2890774149C204787440 @default.
• W2890774149 hasConceptScore W2890774149C27081682 @default.
• W2890774149 hasConceptScore W2890774149C2776260265 @default.
• W2890774149 hasConceptScore W2890774149C2777575956 @default.
• W2890774149 hasConceptScore W2890774149C2779384505 @default.
• W2890774149 hasConceptScore W2890774149C2779745271 @default.
• W2890774149 hasConceptScore W2890774149C2779786854 @default.
• W2890774149 hasConceptScore W2890774149C2781059491 @default.
• W2890774149 hasConceptScore W2890774149C2908647359 @default.
• W2890774149 hasConceptScore W2890774149C71924100 @default.
• W2890774149 hasConceptScore W2890774149C99454951 @default.
• W2890774149 hasFunder F4320307758 @default.
• W2890774149 hasIssue "2" @default.
• W2890774149 hasLocation W28907741491 @default.
• W2890774149 hasLocation W28907741492 @default.
• W2890774149 hasLocation W28907741493 @default.
• W2890774149 hasLocation W28907741494 @default.
• W2890774149 hasLocation W28907741495 @default.
• W2890774149 hasLocation W28907741496 @default.
• W2890774149 hasOpenAccess W2890774149 @default.
• W2890774149 hasPrimaryLocation W28907741491 @default.
• W2890774149 hasRelatedWork W2068695759 @default.

• next